Last updated on November 2019

A 24-week multicenter, randomized, double-blind, parallel-group study comparing the efficacy and safety of ixekizumab to guselkumab in patients with moderate-to-severe plaque psoriasis.


Brief description of study

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

 

Clinical Study Identifier: TX217786

Find a site near you

Start Over

Olympian Clinical Research

Located in: Largo, Florida United States
4.94miles
  Connect »